This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Shu, L.
Right arrow Articles by Houghton, P. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shu, L.
Right arrow Articles by Houghton, P. J.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, September 2009, p. 4691-4700, Vol. 29, No. 17
0270-7306/09/$08.00+0     doi:10.1128/MCB.00764-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

The mTORC2 Complex Regulates Terminal Differentiation of C2C12 Myoblasts{triangledown}

Lili Shu and Peter J. Houghton*

Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794

Received 12 June 2009/ Accepted 20 June 2009

Rapamycin, a selective inhibitor of mTORC1 signaling, blocks terminal myoblast differentiation. We found that downregulation of rictor, a component of the mTORC2 complex, but not downregulation of raptor, a component of the mTORC1 complex, prevented terminal differentiation (fusion) of C2C12 myoblasts. Both rapamycin and rictor downregulation suppressed the phosphorylation of AKT(S473), and rapamycin treatment of C2C12 myoblasts disrupted the mTORC2 complex. Importantly, downregulation of rictor inhibited TORC2 signaling without inhibiting mTORC1 signaling, suggesting that inhibition of mTORC1 by rapamycin may not be the cause of arrested differentiation. In support of this, expression of a phosphomimetic mutant AKT(S473D) in rictor-deficient cells rescued myoblast fusion even in the presence of rapamycin. mTORC2 signaling to AKT appears necessary for downregulation of the Rho-associated kinase (ROCK1) that occurs during myogenic differentiation. Rapamycin treatment prevented ROCK1 inactivation during differentiation, while suppression of ROCK1 activity during differentiation and myoblast fusion was restored through expression of AKT(S473D), even in the presence of rapamycin. Further, the ROCK inhibitor Y-27632 restored terminal differentiation in rapamycin-treated myoblasts. These results provide the first evidence of a specific role for mTORC2 signaling in terminal myogenic differentiation.

* Corresponding author. Mailing address: Department of Molecular Pharmacology, St. Jude Children's Research Hospital, 332 N. Lauderdale St., Memphis, TN 38105-2794. Phone: (901) 595-3440. Fax: (901) 595-4290. E-mail: peter.houghton{at}stjude.org

{triangledown} Published ahead of print on 29 June 2009.

Molecular and Cellular Biology, September 2009, p. 4691-4700, Vol. 29, No. 17
0270-7306/09/$08.00+0     doi:10.1128/MCB.00764-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»